It is with great pride and enthusiasm that GC Biotherapeutics Inc. (GCBT) has now established its foundation in Canada by building the country`s first and only commercial-scale intravenous immunoglobulin (IVIG) and albumin manufacturing facility. The GC family has been providing patients with safe and effective healthcare solutions adapted to their evolving needs since its inception in 1967. The construction of this state-of-the-art bio-manufacturing center and North American headquarters in Montreal is a cornerstone of our international growth strategy, and a historic milestone beneficial to the Canadian healthcare environment.
We are honored that our extensive expertise will contribute to Canadians’ health. Moreover, we are excited to combine our accumulated knowledge and experience with the highly qualified people that we will be recruiting here. Canada and Quebec’s life science industries are well known worldwide for quality professionals and their capacity to innovate.
As an emerging global leader in the healthcare industry, our purpose is to provide our customers with the best and safest therapeutic products. GCBT’s devotion to the healthy lives of people is our ultimate mission. Although we must still reach some important milestones before the commercial launch, GCBT is already fully active and planning for the years ahead.
We thank you for your interest and will continue to dedicate our efforts to making this project a success for the life science industry and most of all, to move forward toward a healthier world.
We will embrace the Great Challenge! We are GCBT!
Jae Hyun Bae | Chief Executive Officer
Jae Hyun Bae | CEO